About Exelixis (NASDAQ:EXEL)

Exelixis, Inc. is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company's cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors. The Company's CABOMETYX tablets are approved for previously treated advanced kidney cancer and COMETRIQ capsules are approved for progressive, metastatic medullary thyroid cancer. The third product, Cotellic, is a formulation of cobimetinib, a selective inhibitor of MEK is approved as part of a combination regimen to treat advanced melanoma. Both cabozantinib and cobimetinib have shown potential in a range of forms of cancer and are the subjects of broad clinical development programs. The Company's XL888 is a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90), a molecular chaperone protein.

Receive EXEL News and Ratings via Email

Sign-up to receive the latest news and ratings for EXEL and its competitors with MarketBeat's FREE daily newsletter.

Profitability

Miscellaneous

Exelixis (NASDAQ:EXEL) Frequently Asked Questions

What is Exelixis' stock symbol?

Exelixis trades on the NASDAQ under the ticker symbol "EXEL."

How were Exelixis' earnings last quarter?

Exelixis (NASDAQ:EXEL) posted its quarterly earnings results on Monday, February, 26th. The biotechnology company reported $0.12 EPS for the quarter, hitting the consensus estimate of $0.12. The biotechnology company had revenue of $120.10 million for the quarter, compared to analyst estimates of $120.25 million. Exelixis had a return on equity of 81.05% and a net margin of 34.08%. The company's quarterly revenue was up 54.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.12 EPS. View Exelixis' Earnings History.

When will Exelixis make its next earnings announcement?

Where is Exelixis' stock going? Where will Exelixis' stock price be in 2018?

11 analysts have issued 1 year price objectives for Exelixis' stock. Their predictions range from $28.00 to $40.00. On average, they expect Exelixis' share price to reach $34.00 in the next year. View Analyst Ratings for Exelixis.

What are Wall Street analysts saying about Exelixis stock?

Here are some recent quotes from research analysts about Exelixis stock:

1. According to Zacks Investment Research, "Exelixis put up a strong performance in 2017 driven by gain in market share for Cabometyx. However, Exelixis is heavily dependent on Cabometyx for growth. Competition might stiffen up in 2018 as the FDA accepted Bristol-Myers’ supplemental Biologics License Application for priority review of Opdivo plus Yervoy to treat intermediate- and poor-risk patients with advanced RCC with an action date in Apr 2018. Moreover, there has been a slowdown in demand of Cabometyx in recent times. Meanwhile, sales are expected to get a further boost as the company will launch the drug for first-line RCC which will increases the eligible patient population for Caobometyx in the United States. A potential label expansion for advanced HCC will further boost the growth prospects." (3/13/2018)

2. Cann analysts commented, "Based on the speed that Exelixis’ pipeline is advancing, we are adjusting the timing of acceleration of the R&D ramp to now start in 2018. We are increasing our estimated 2018 R&D to $207.3 million from our prior $156.9 million; and to $228.0 million in 2019 from our prior $164.6 million. The net result is a 30.2% decrease in our estimated 2018 EPS, and a 15.1% decrease in our estimated 2019 EPS. We are aligning operating expenses in 2020-22, assigning more expense to R&D, but not making changes to total operating expenses. As a result, our estimated EPS for 2020-22 remain unchanged." (3/8/2018)

Are investors shorting Exelixis?

Exelixis saw a decrease in short interest in February. As of February 15th, there was short interest totalling 14,667,033 shares, a decrease of 9.1% from the January 31st total of 16,143,386 shares. Based on an average trading volume of 2,463,155 shares, the days-to-cover ratio is currently 6.0 days. Currently, 5.1% of the shares of the stock are sold short.

Has Exelixis been receiving favorable news coverage?

Media coverage about EXEL stock has been trending somewhat positive on Monday, Accern reports. The research firm identifies positive and negative press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Exelixis earned a daily sentiment score of 0.12 on Accern's scale. They also gave media coverage about the biotechnology company an impact score of 49.22 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

Which major investors are buying Exelixis stock?

EXEL stock was purchased by a variety of institutional investors in the last quarter, including American Century Companies Inc., Jennison Associates LLC, Smith Asset Management Group LP, Caisse DE Depot ET Placement DU Quebec, Arrowstreet Capital Limited Partnership, Stephens Investment Management Group LLC, Bank of Montreal Can and Macquarie Group Ltd.. View Insider Buying and Selling for Exelixis.

How do I buy shares of Exelixis?

Shares of EXEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Exelixis' stock price today?

One share of EXEL stock can currently be purchased for approximately $24.43.

How big of a company is Exelixis?

Exelixis has a market capitalization of $7.30 billion and generates $452.48 million in revenue each year. The biotechnology company earns $154.22 million in net income (profit) each year or $0.49 on an earnings per share basis. Exelixis employs 372 workers across the globe.

How can I contact Exelixis?

Exelixis' mailing address is 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-837-7000 or via email at [email protected]

MarketBeat Community Rating for Exelixis (EXEL)

MarketBeat's community ratings are surveys of what our community members think about Exelixis and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Exelixis (NASDAQ:EXEL) Analysts' Consensus Rating

MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.

MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.